So, here's a thing that happens in the drug business: a company spends years and billions developing a treatment, gets it approved, and then immediately starts worrying about the next company that might come along with something better. Or at least different. This week, that story is playing out in the psoriasis market.
On Wednesday, the U.S. Food and Drug Administration said yes to a new drug called Icotyde. Its technical name is icotrokinra, and it's a pill you take once a day for moderate-to-severe plaque psoriasis. It's approved for adults and for kids as young as 12.
This isn't just any new drug. It's the result of a partnership between two companies: Protagonist Therapeutics, Inc. (PTGX) and the healthcare giant Johnson & Johnson (JNJ). They discovered it together under a collaboration deal. Johnson & Johnson gets to run with it from Phase 2 trials onward and has the exclusive worldwide rights to sell it for a bunch of different potential uses.
For Protagonist, the FDA's thumbs-up means a nice, immediate payday. The approval triggers a $50 million milestone payment from J&J to Protagonist. And that's just the start. Protagonist is also in line to receive up to $580 million more in potential future payments tied to regulatory and sales milestones, plus tiered royalties based on how well the drug sells. Not a bad deal for a smaller biotech.
So what's the big deal about this pill? Johnson & Johnson is calling it the first and only oral peptide that targets the interleukin-23 (IL-23) receptor. In simpler terms, it's a pill that goes after a specific pathway involved in psoriasis inflammation. The promise is complete skin clearance with a safety profile that looks good, all in a convenient daily pill. For many patients, that's a lot more appealing than an injection.
What the Data Shows
The FDA's decision wasn't a shot in the dark. It's based on a hefty package of data from something called the ICONIC clinical development program. This included four Phase 3 studies with about 2,500 patients total.
The drug hit all its primary goals in the trials and showed that favorable safety profile. The studies looked at Icotyde in both adults and adolescents, checked how it worked on tough spots like the scalp and genital areas, and even ran head-to-head trials against an existing active treatment to see how it stacked up. The data, in short, was solid enough to convince the regulators.
And Then There's the Competition
Whenever a new player enters a lucrative market, someone else usually feels a pinch. In this case, that someone is AbbVie Inc (ABBV).
AbbVie's stock took a dip on the news. Why? Because AbbVie sells a hugely successful drug for plaque psoriasis called Skyrizi (risankizumab-rzaa). It's also an IL-23 inhibitor, but it's given as a subcutaneous injection every three months after an initial loading period.
Analysts at BNP Paribas Equity Research wrote that Icotyde's approval "may represent competition" to Skyrizi. The thinking is straightforward: some patients and doctors might prefer a daily pill over a quarterly shot, even if the shot is highly effective and has compliance benefits of its own (you can't forget a dose you only take four times a year).
Analyst Navann Ty noted that Skyrizi is still very well-positioned thanks to its strong efficacy. But the arrival of a convenient oral option changes the conversation.
A Bigger Pie, or Just Different Slices?
Here's an interesting twist in the competitive drama. Both Johnson & Johnson and AbbVie have suggested that having an oral therapy on the market could actually be good for business—for everyone.
The logic goes like this: right now, only about 30-40% of eligible psoriasis patients are on advanced systemic treatments. A pill might be less intimidating than an injection for some people. If an oral option brings more patients into the treated pool, it could expand the entire market. That means Skyrizi could still have room to grow even with a new competitor, because the pie itself gets bigger.
But the competition might not stop at psoriasis. Icotyde is also being studied for active psoriatic arthritis, ulcerative colitis, and Crohn's disease. If it gets approved for those, it would compete with Skyrizi in even more arenas. Skyrizi is a key growth driver for AbbVie; BNP Paribas forecasts it will grow 23% in fiscal 2026.
The market reaction was clear: AbbVie shares closed 5.20% lower at $208.34 on Thursday. When a new pill gets approved, someone else's stock often gets a headache.
